Skip to main content

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines

Michaelis, Martin, Voges, Yvonne, Rothweiler, Florian, Weipert, Fabian, Zia-Ahmad, Amara, Cinatl, Jaroslav, von Deimling, Andreas, Westermann, Frank, Rödel, Franz, Wass, Mark N., and others. (2020) Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines. Cancers, 12 (3). p. 577. ISSN 2072-6694. (doi:10.3390/cancers12030577) (KAR id:80405)

PDF Publisher pdf
Language: English


Creative Commons Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.
Download (1MB) Preview
[img]
Preview
Official URL
https://dx.doi.org/10.3390/cancers12030577

Abstract

The survivin suppressant YM155 is a drug candidate for neuroblastoma. Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). Seventy seven (77) cell lines displayed YM155 IC\(_{50}\)s in the range of clinical YM155 concentrations. ABCB1 was an important determinant of YM155 resistance. The activity of the ABCB1 inhibitor zosuquidar ranged from being similar to that of the structurally different ABCB1 inhibitor verapamil to being 65-fold higher. ABCB1 sequence variations may be responsible for this, suggesting that the design of variant-specific ABCB1 inhibitors may be possible. Further, we showed that ABCC1 confers YM155 resistance. Previously, p53 depletion had resulted in decreased YM155 sensitivity. However, \(TP53\)-mutant cells were not generally less sensitive to YM155 than \(TP53\) wild-type cells in this study. Finally, YM155 cross-resistance profiles differed between cells adapted to drugs as similar as cisplatin and carboplatin. In conclusion, the large cell line panel was necessary to reveal an unanticipated complexity of the YM155 response in neuroblastoma cell lines with acquired drug resistance. Novel findings include that ABCC1 mediates YM155 resistance and that YM155 cross-resistance profiles differ between cell lines adapted to drugs as similar as cisplatin and carboplatin.

Item Type: Article
DOI/Identification number: 10.3390/cancers12030577
Uncontrolled keywords: YM155; survivin; neuroblastoma; drug resistance; ABCB1; ABCC1
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculties > Sciences > School of Biosciences
Depositing User: Martin Michaelis
Date Deposited: 08 Mar 2020 09:05 UTC
Last Modified: 11 Mar 2020 14:36 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/80405 (The current URI for this page, for reference purposes)
Michaelis, Martin: https://orcid.org/0000-0002-5710-5888
Wass, Mark N.: https://orcid.org/0000-0001-5428-6479
  • Depositors only (login required):

Downloads

Downloads per month over past year